30 to 40+ % is pretty staggering when you think about it. It ought to be far more than sufficient to induce glaucoma doctors and general ophthalmologists to sit up and pay more attention to what they're prescribing to their glaucoma and ocular hypertension patients.
Risk factors to develop ocular surface disease
in treated glaucoma or ocular hypertension patients.
To identify risk factors for developing ocular surface disease (OSD), to verify the prevalence
I don't get it.
OK it looks like a well done study with important results.
There are approximately a gajillion published studies on the sins of BAK against the cornea and beyond, and we have to kill more bunnies to re-prove it how many more times? Quit using the durned stuff already. It's not like we don't have other effective preservatives. Oh, and lest we forget, ever heard of preservative-free?
A new safety concern for glaucoma treatment demonstrated bymass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits.
Corneal epithelial toxicity of antiglaucoma formulations: in vitro study of repeated applications.
By using a biologically relevant and sensitive three-dimensional model of human corneal epithelium and multiple endpoint analysis, assessment of the potential for eye irritation and long-term compatibility of four registered ophthalmological preparations, ie, Timolabak(®), Timoptol(®), Nyogel(®), and Timogel(®), was performed. This approach enables classification of
Benzalkonium chloride breaks down conjunctival immunological tolerance in a murine model.
The impact of topical eye drops with benzalkonium chloride (BAK) as a preservative could involve more than the reported toxic effects on the ocular surface epithelium and ultimately affect the immune balance of the conjunctiva. We found that BAK not only impairs tolerance induction in a murine model, but leads to mild systemic immunization. Contrasting with antigen only-treated mice,
You all know my soapbox! Thankfully, more and more doctors are paying attention to those glaucoma medication side effects (including the fact that dry eye side effects may cause patients to be less compliant) and more preservative-free options are coming on the market.
This study compares efficacy of an unpreserved glaucoma drop (Catioprost) versus a popular BAK-preserved one (Xalatan).
A Comparative Study of a Preservative-Free Latanoprost Cationic Emulsion (Catioprost(®)) and a BAK-Preserved Latanoprost Solution in Animal Models.